Cancer Genetics and Epigenetics

摘要 Sidney Kimmel综合癌症中心（SKCCC）癌症遗传学和表观遗传学（CGE） 该计划的总体目标是加强对细胞和组织中癌症发生和发展的理解， 分子生物学水平。研究结果通过该计划内的试验转化，更常见的是， 与其他SKCCC项目合作，为临床试验和生物标志物工作提供概念。的 SKCCC优先考虑驱动个体人类癌症的遗传和表观遗传改变的定义， 以发展个性化的癌症护理。为了实现其目标，CGE计划领导和成员 实际上，已将其纳入SKCCC的所有活动中，包括关键的行政活动、协作工作 与几乎所有的SKCCC计划，并利用和管理SKCCC共享资源。的 该计划由38名计划正式成员组成，其中31人拥有同行评审资金，另外两人 准会员，包括在上一个资助期内获得K奖的准会员。该计划已 成员在约翰霍普金斯两所学校的九个部门任职。总的直接癌症- 该计划的相关同行评审资金为1130万美元，其中770万美元来自国家癌症研究所。 院自上次审查以来，计划成员的出版物总数为807篇，其中197篇（24.4%） 383个（47.5%）是方案内合作，616个（76.3%）是方案间合作。的 影响因子>10的期刊占23.4%，影响因子>25的期刊占8.8%。 在医学博士尼尔·阿扎德的指导下; Stephen Baylin，医学博士;和医学博士维克托·维尔库列斯库哲学博士、的 咨询小组方案的具体目标是： 目的1：确定驱动人类癌症发生和进展的遗传异常， 特别是那些可能适合于治疗或诊断干预的药物。 目的2：描述肿瘤发生的分子和表观遗传学变化， 进展，并利用这些信息来设计治疗策略， 生物标志物方法。 目标3：将基本发现转化为临床前研究，为临床研究提供概念 由CGE计划成员和其他SKCCC计划成员领导的由制药商发起的试验。 这些目标丰富了SKCCC的翻译目标，特别是在设计新的治疗范例方面 对于许多常见类型的人类恶性肿瘤，并推导出基于分子的生物标志物策略， 癌症检测、预后预测和监测癌症进展。

ABSTRACT The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Genetics and Epigenetics (CGE) Program's overall goal is to enhance understanding of the initiation and progression of cancer at a cellular and molecular biology level. Findings are translated through trials within the Program and, more often, by contributing concepts to clinical trials and biomarker efforts in collaboration with other SKCCC Programs. The SKCCC prioritizes the definition of the genetic and epigenetic alterations that drive individual human cancers in order to develop personalized cancer care. To implement its aims, CGE Program Leadership and Membership are integrated into virtually all activities in the SKCCC, including key administrative activities, collaborative work with virtually all of the SKCCC Programs, and utilization and management of SKCCC Shared Resources. The Program consists of 38 Program full Members, 31 of whom have peer-reviewed funding, and an additional two Associate Members, including one with an active K awards during this last funding period. The Program has members with appointments in nine departments across two schools at Johns Hopkins. The total direct cancer- relevant peer-reviewed funding for the Program is $11.3 million, with $7.7 million from the National Cancer Institute. The total number of publications by Program members since last review is 807, of which 197 (24.4%) are Intra-Programmatic, 383 (47.5%) are Inter-Programmatic and 616 (76.3%) have external collaborations. Of these publications, 23.4% are in journals with impact factors >10 and 8.8% in journals with impact factors >25. Under the direction of Nilofer Azad, M.D.; Stephen Baylin, M.D.; and Victor Velculescu, M.D., Ph.D., the Specific Aims of the CGE Program are: Aim 1: To define genetic abnormalities that drive human cancer initiation and progression, particularly those that may be amenable to therapeutic or diagnostic intervention. Aim 2: To characterize the molecular and epigenetic changes that underlie tumor initiation and progression, and harness this information to design therapeutic strategies and devise biomarker approaches. Aim 3: To translate basic findings to preclinical studies to provide concepts for clinical investigator-initiated trials led by CGE Program Members and other SKCCC Program Members. These aims enrich the translational goals of the SKCCC, particularly in designing new therapy paradigms for many common types of human malignancies and deriving molecularly based biomarker strategies for early cancer detection, prognostic prediction and monitoring cancer progression.